Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22697290 | 0.94 | ALDH1A1 (0.50) | CYP3A4CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL32677628 | 0.86 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL25597961 | 0.85 | DPP4 (0.50) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL25597434 | 0.85 | DPP4 (0.50) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL25597432 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL8234039 | 0.83 | CTSL (0.59) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL20825664 | 0.82 | EPHX1 (0.56) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL25597428 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL7810127 | 0.80 | ALDH1A1 (0.54) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 | |
| SCHEMBL7333566 | 0.80 | ALDH1A1 (0.54) | CYP3A4CYP2C9CYP2C19EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CYP3A4 3130/4885CYP2C9 4370/4885CYP2C19 3540/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CYP3A4 3130/4885CYP2C9 4370/4885CYP2C19 3540/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | CYP3A4 3130/4885CYP2C9 4370/4885CYP2C19 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.